New observations on factor XI deficiency.
Factor (F) XI is an injury-related bleeding tendency that commonly occurs when trauma involves tissues rich in fibronolytic activators. Severe FXI deficiency is defined when the activity of FXI in plasma is less than 15 U dL(-1). The disorder is inherited as an autosomal recessive trait manifesting in homozygotes or compound heterozygotes, and infrequently in heterozygotes. So far 53 mutations in the gene of FXI have been described and four of them were found to be prevalent in Ashkenazi Jews, Iraqi Jews, Basques or the English population. For each of the four mutations a founder effect was discerned. Inhibitors can develop in patients with FXI level < 1U dL(-1) who were exposed to plasma which seriously complicates their management during surgery. No correction of a prolonged aPTT by normal plasma is indicative of the presence of an inhibitor. In contrast to patients with haemophilia A, severe FXI deficiency provides no protection against myocardial infarction. In patients with severe FXI deficiency undergoing surgery, fresh frozen plasma is the treatment of choice. FXI concentrates can also be used but cause thrombosis in approximately 10% of patients, particularly those with cardiovascular disease. Recombinant FVIIa has successfully prevented bleeding during or after surgery in patients with FXI inhibitors.
Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer, Israel. ophiras@sheba.health.gov.il
O
O
Salomon
U
U
Seligsohn
D016063:Blood Loss, Surgical / Q000517:prevention & control; D005172:Factor XI / Q000032:analysis / Q000037:antagonists & inhibitors / Q000235:genetics; D005173:Factor XI Deficiency / Q000150:complications*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D009154:Mutation; D011994:Recombinant Proteins / Q000032:analysis / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000209:etiology
D011994:Recombinant Proteins; D005172:Factor XI